Information service on new and emerging health technologies: Identification and prioritization processes for a European Union–wide newsletter

Wild, Claudia; Simpson, Sue; Douw, Karla; Geiger-Gritsch, S.; Mathis, Simon; Langer, Thomas

doi:10.1017/s0266462309990687

Cited by 9 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-launch activities include horizon scanning for new medicines to prepare for the future. Horizon scanning for medicines is defined as “ identifying new medicines or new uses of existing medicines that are expected to receive marketing authorization from the Regulatory Authority in the near future and estimating their potential impact on patient care ” (113, 130, 131), with activities growing across countries and regions (131–137). This includes recent proposals for cross country collaboration in Horizon Scanning (137).…”

Section: Results—ongoing Initiativesmentioning

confidence: 99%

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Godman

Bucsics²,

Bonanno

et al. 2018

Front. Public Health

132

137

View full text Add to dashboard Cite

Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective.Methods: A narrative review of pharmaceutical policies and implications, as well as possible developments, based on key publications and initiatives known to the co-authors principally from a health authority perspective.Results: A number of initiatives and approaches have been identified including new models to better manage the entry of new medicines based on three pillars (pre-, peri-, and post-launch activities). Within this, we see the growing role of horizon scanning activities starting up to 36 months before launch, managed entry agreements and post launch follow-up. It is also likely there will be greater scrutiny over the effectiveness and value of new cancer medicines given ever increasing prices. This could include establishing minimum effectiveness targets for premium pricing along with re-evaluating prices as more medicines for cancer lose their patent. There will also be a greater involvement of patients especially with orphan diseases. New initiatives could include a greater role of multicriteria decision analysis, as well as looking at the potential for de-linking research and development from commercial activities to enhance affordability.Conclusion: There are a number of ongoing activities across countries to try and fund new valued medicines whilst attaining or maintaining universal healthcare. Such activities will grow with increasing resource pressures and continued unmet need.

show abstract

Section: Results—ongoing Initiativesmentioning

confidence: 99%

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Godman

Bucsics²,

Bonanno

et al. 2018

Front. Public Health

132

137

View full text Add to dashboard Cite

show abstract

“…Cooperation to evaluate and debate these key issues is ongoing starting pre-launch (67). Organisations involved include EuroScan (133,169), the Piperska group (who provided the majority of co-authors for this paper (10, 129)), EUnetHTA , which is working on EU-wide collaboration producing product evaluations and the MEDEV group representing the payers. Co-operation is demonstrated by the proposed model to improve the managed entry of new medicines (Figure 1) as well as the initiation of MoCA to develop potential frameworks to value new OMPs (Table 4).…”

Section: Discussionmentioning

confidence: 99%

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman

Malmström

Diogène³

et al. 2014

Expert Review of Clinical Pharmacology

116

132

View full text Add to dashboard Cite

Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems?Godman B 1,2,3 , Malmström RE 4 , Diogene E 5 , Gray A 6 , Jayathissa S 7 , Timoney A 8 , Acurcio FA 9,10 , Alkan A 11 , Brzezinska A 12 , Bucsics A 13 , Campbell S 14,15 AbstractIntroduction: Medicines have made an appreciable contribution to improving health. However, even high income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimise their use. Objective: Review case histories among health authorities to improve the utilisation and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. Challenges and proposed models: A number of issues and challenges have been identified including the limited innovation level of new medicines alongside increasing requested prices for their reimbursement especially for oncology, orphan diseases, diabetes and HCV. Models centre on the three pillars of pre-, peri, and post-launch including critical drug evaluation and multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure Discussion: Proposed models which involve all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

show abstract

“…29 Also in relation to horizon scanning, EUnetHTA produced a newsletter on new and emerging health technologies for policy-makers in collaboration with EuroScan. 30,31 Core HTA and an adaptation toolkit are two types of HTA product for co-producing or translating HTA reports from other countries that partners in EUnetHTA have developed with the aim of reducing duplication of work and promoting existing reports from other countries. Core HTA built on recommendations from previous projects and developed a specific structure for undertaking and reporting HTA.…”

Section: Research Within the Last Decadementioning

confidence: 99%

Health technology assessment: Research trends and future priorities in Europe

Nielsen

Funch

Kristensen³

2011

J Health Serv Res Policy

View full text Add to dashboard Cite

The research priorities identified are important for obtaining high quality and cost-effective health care in Europe. Managing the introduction, use and phasing out of technologies challenges health services throughout Europe, and these processes need to be improved to successfully manage future more general challenges. An ageing population and a diminishing workforce both require strong efforts to ensure effective and well-organized use of human resources and technologies. Furthermore, Europe needs to focus on innovation. This is closely linked to use of technologies and calls for future research.

show abstract

Information service on new and emerging health technologies: Identification and prioritization processes for a European Union–wide newsletter

Cited by 9 publications

References 12 publications

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Health technology assessment: Research trends and future priorities in Europe

Contact Info

Product

Resources

About